404

Not Found

Is this what you were looking for?

healthcare bayer com
By Chris Anderson

Bayer nabs Direvo for $300 million

Bayer HealthCare last week announced its acquisition of Direvo Biotech AG in an all-cash deal at a transaction value of E210 million or approximately $300 million.
By Jeffrey Bouley

Ardea Biosciences earns $15 million clinical milestone payment from Bayer HealthCare

Achievement is part of an April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase inhibitor compounds for cancer and other indications. The current milestone was triggered by the initiation of a Phase II clinical study evaluating BAY 86-9766 in combination with sorafenib for the treatment of hepatocellular carcinoma
By Kelsey Kaustinen

Bayer, Onyx Pharmaceuticals restructure Nexavar partnership

Onyx Pharmaceuticals, Inc. and Bayer HealthCare announced today the restructuring of their long-term partnership for the global development and marketing of Nexavar (sorafenib) tablets, and also entered into a new agreement related to Bayer’s late-stage oncology compound, regorafenib.
By Kelsey Kaustinen

Bayer divests Diabetes Care business for $1.15B

Bayer inked a definitive agreement with Panasonic Healthcare Holdings under which the latter will acquire its Diabetes Care business, which saw sales of 909 million euros last year
By Stephen Albainy-Jenei

Bayer sues Abbott over Humira; Abbott thanks them with their own lawsuit

Last month, Abbott Laboratories was sued by Bayer AG’s HealthCare unit, alleging that Abbott's best-selling drug Humira infringes on a Bayer patent. In one new twist, Abbott has sued Bayer AG’s HealthCare unit, claiming the Bayer patent is invalid, not infringed or unenforceable.

Run a Search

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue